Genpharmasec

Genpharmasec

1.52
-0.05
(-3.18%)
hide
Key Fundamentals
Add Ratio
Market Cap
86.90 Cr
EPS
0.02
PE Ratio
157.00
Dividend Yield
0.00 %
52 Week High
4.32
52 Week Low
1.42
PB Ratio
1.32
Debt to Equity
0.07
Forecast For
Actual

Company News

View All News
Caret
neutral
Genpharmasec Limited Resubmits Clear Copy of Q2 FY2026 Financial Results6 days ago
Genpharmasec Limited resubmitted clear copies of its financial results for the quarter and half year ended September 30, 2025, following BSE's request due to unclear figures in the previously submitted PDF. The company's standalone results showed total income of Rs 3,639.16 lakhs for the half year, with profit before tax of Rs 308.65 lakhs for the quarter. The consolidated results included subsidiaries Clinigenome India Private Limited (99.99% stake), Genpharmasec Middle East DMCC (52% stake), and Derren Healthcare Private Limited (70% stake). The financial results were reviewed by the Audit Committee and approved by the Board of Directors on November 6, 2025. The auditor's review found no material misstatements in the financial statements prepared in accordance with Indian Accounting Standards.
neutral
Genpharmasec Limited Reports No Deviation in Rights Issue Fund UtilizationNov 06, 2025
Genpharmasec Limited confirmed no deviation or variation in the use of proceeds from its Rights Issue for the quarter ended September 30, 2025. The company utilized funds as originally planned across four key objectives: Rs. 1443.58 lakhs to acquire equity shares from shareholders of Derren Healthcare Private Limited to make it a subsidiary, Rs. 289.00 lakhs out of allocated Rs. 588.00 lakhs to repay term loans, Rs. 1643.86 lakhs out of Rs. 1650.00 lakhs for working capital purposes, and Rs. 25.00 lakhs to meet issue expenses. The statement was reviewed by the Audit Committee and submitted to BSE as per SEBI regulations.
neutral
Genpharmasec Limited Reports Quarterly Financial Results for September 2025Nov 06, 2025
Genpharmasec Limited's Board of Directors approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The company operates primarily in one business segment and has three subsidiaries: Clinigenome India Private Limited (99.99% stake), Genpharmasec Middle East DMCC (52.00% stake), and Derren Healthcare Private Limited (70.00% stake). The board meeting was held on November 6, 2025, commencing at 5:30 p.m. and concluding at 7:25 p.m. The financial statements were prepared in accordance with Indian Accounting Standards and reviewed by auditors Bilimoria Mehta & Co.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
290.40
#1 23,171.80
12.18
#1 99,561.70
11.11
#1 1,821
23.79
58.87
121.85
20,500.80
83.28
551.40
#1 55,040.00
70
117.20
30.98
64.62
9,816.00
44.54
262.80
28.63
87
255.83
38.41
508.75
3,695.60
#1 8.88
387.50
-25.38
407
14.46
38.36
379.90
3,629.80
53.88
367.20
5,071.83
20
414.04
49.69
171.28
3,026.90
44.09
262.20
79.10
23
#1 2,700.00
61.16
166.18
2,201.50
36.54
312.50
136.92
40
137.33
57.35
521.00
1,883.90
39.86
89.60
14.72
42
11.83
33.26
36.00
1,221.10
454.63
81.30
15.16
3
0.00
31.85
36,700.00
1,121.80
12.85
67.60
-16.34
115
-51.77
54.95
Growth Rate
Revenue Growth
18.33 %
Net Income Growth
-700.00 %
Cash Flow Change
201.36 %
ROE
-826.92 %
ROCE
243.75 %
EBITDA Margin (Avg.)
276.11 %

Quarterly Financial Results

Quarterly Financials
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
6
6
8
7
11
6
7
9
15
13
33
Expenses
6
6
8
6
10
5
6
8
15
11
33
EBITDA
0
0
0
0
0
1
1
2
-0
2
0
Operating Profit %
3 %
0 %
-1 %
0 %
-0 %
4 %
2 %
9 %
-7 %
8 %
-1 %
Depreciation
0
0
0
0
0
0
0
0
0
0
1
Interest
0
0
0
0
0
0
0
0
0
0
0
Profit Before Tax
0
0
0
0
0
1
1
1
-0
1
-1
Tax
-1
0
0
0
0
0
-0
1
-0
0
0
Net Profit
1
0
0
0
-0
0
1
1
-0
1
-1
EPS in ₹
0.04
0.00
0.00
0.00
0.01
0.01
0.01
0.01
-0.01
0.02
-0.02

Balance Sheet

Balance Sheet
2023
2024
2025
Total Assets
20
71
80
Fixed Assets
0
1
8
Current Assets
19
41
27
Capital Work in Progress
0
0
0
Investments
1
19
19
Other Assets
19
51
54
Total Liabilities
20
71
80
Current Liabilities
2
3
10
Non Current Liabilities
3
4
5
Total Equity
15
65
65
Reserve & Surplus
-12
9
10
Share Capital
28
55
55

Cash Flow

Cash Flow
2023
2024
2025
Net Cash Flow
0
17
-14
Investing Activities
0
-28
-15
Operating Activities
-3
-3
3
Financing Activities
3
48
-1

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Feb 2024
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
59.96 %
59.96 %
59.96 %
59.96 %
59.96 %
59.96 %
59.96 %
59.96 %
59.96 %
59.96 %
59.96 %
59.96 %
29.98 %
29.98 %
29.98 %
29.98 %
29.98 %
29.98 %
29.98 %
29.98 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
24.56 %
24.43 %
25.21 %
26.18 %
30.02 %
30.36 %
30.58 %
30.57 %
30.13 %
31.81 %
32.82 %
33.81 %
52.78 %
56.17 %
61.26 %
59.55 %
59.62 %
59.94 %
60.03 %
60.19 %
Others
15.49 %
15.61 %
14.83 %
13.86 %
10.03 %
9.68 %
9.46 %
9.47 %
9.91 %
8.23 %
7.21 %
6.23 %
17.24 %
13.84 %
8.76 %
10.47 %
10.40 %
10.08 %
9.99 %
9.83 %
No of Share Holders
0
6,265
9,559
17,121
24,134
54,007
53,404
53,266
49,760
48,868
54,458
89,438
1,05,693
1,08,137
1,08,220
1,05,838
1,09,206
1,09,080
1,07,602
1,05,804

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
06 Sept 2021 CHANGE OF NAME Change Of Name
NA
06 Sept 2021 4.97 4.97
09 Jan 2024 RIGHTS Rights
1:1
09 Jan 2024 2.87 5.23
23 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
23 Jul 2024 1.99 2.20
12 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Nov 2024 3.14 2.95
10 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
10 Feb 2025 2.53 2.24
21 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
21 May 2025 2.05 2.24
07 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Aug 2025 1.99 1.99
29 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
29 Sept 2025 1.93 1.95
06 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Nov 2025 1.77 1.57

Announcements

Submission Of Clear Copy Of Financial Results For The Quarter And Half Year Ended September 30 2025.7 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication10 days ago
Statement Of Deviation Or Variation In The Use Of Proceeds Of Rights Issue For The Quarter Ended 30Th September 2025.Nov 06, 2025
Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter & Half Year Ended 30Th September 2025.Nov 06, 2025
Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Held On Thursday November 06 2025.Nov 06, 2025
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday 06Th November 2025.Oct 27, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 30, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 29, 2025
Closure of Trading WindowSep 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 06, 2025
Reg. 34 (1) Annual Report.Sep 05, 2025
Notice Of 33Rd Annual General Meeting Of The Company To Be Held On September 29 2025. Sep 05, 2025
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sSep 02, 2025
Intimation Of Book Closure For Annual General MeetingSep 02, 2025
Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Held On Tuesday 02Nd September 2025.Sep 02, 2025
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Tuesday 02Nd September 2025.Aug 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Statement Of Deviation Or Variation In The Use Of Proceeds Of Rights Issue For The Quarter Ended 30Th June 2025.Aug 07, 2025
Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter Ended 30Th June 2025. Aug 07, 2025
Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Held On Thursday 07Th August 2025.Aug 07, 2025
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday 07Th August 2025.Aug 01, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 25, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Closure of Trading WindowJun 26, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 23, 2025
Statement Of Deviation Or Variation In The Use Of Proceeds Of Rights Issue For The Quarter Ended 31St March 2025.May 21, 2025
Audited Standalone & Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended 31St March 2025.May 21, 2025
Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Held On Wednesday May 21 2025.May 21, 2025
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday 21St May 2025.May 13, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 30, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 07, 2025
Closure of Trading WindowMar 25, 2025
Board Meeting Outcome for Outcome Of The Separate Meeting Of Independent Directors Of The Company.Mar 24, 2025
Board Meeting Intimation for Separate Meeting Of Independent Directors Of The Company To Be Held On Monday March 24 2025.Mar 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 12, 2025
Statement Of Deviation Or Variation In The Use Of Proceeds Of Rights Issue For The Quarter Ended 31St December 2024.Feb 10, 2025
Integrated Filing (Financial)Feb 10, 2025
Result - Financial Results For The Quarter And Nine Months Ended December 31 2024.Feb 10, 2025
Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Held On Monday February 10 2025.Feb 10, 2025
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Monday 10Th February 2025.Feb 03, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 10, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2024
Statement Of Deviation Or Variation In The Use Of Proceeds Of Rights Issue For The Quarter Ended 30Th September, 2024.Nov 12, 2024
Unaudited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2024.Nov 12, 2024
Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Held On Tuesday, November 12, 2024.Nov 12, 2024
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Tuesday, 12Th November, 2024.Nov 05, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 08, 2024

Technical Indicators

RSI(14)
Neutral
39.14
ATR(14)
Less Volatile
0.09
STOCH(9,6)
Neutral
28.99
STOCH RSI(14)
Overbought
84.45
MACD(12,26)
Bullish
0.00
ADX(14)
Strong Trend
27.73
UO(9)
Bearish
37.54
ROC(12)
Downtrend And Accelerating
-11.80
WillR(14)
Neutral
-60.53